Tumor Cell-Derived Nitric Oxide Is Involved in the Immune-Rejection of an Immunogenic Murine Lymphoma

Cancer Research

Volumn 64, Issue 1, 2004, Pages 152-161

  Hu, De En ^a   Dyke, Stephanie O M ^a   Moore, Alistair M ^a   Thomsen, Lindy L ^b   Brindle, Kevin M ^a  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^b GLAXOSMITHKLINE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

N [3 (AMINOMETHYL)BENZYL]ACETAMIDINE; N(G) NITROARGININE METHYL ESTER; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; NITRIC OXIDE SYNTHASE INHIBITOR; NITRITE; RUTHENIUM; SCAVENGER; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CANCER INHIBITION; CELL CULTURE; CELL GROWTH; CONTROLLED STUDY; CYTOKINE RELEASE; ENDOTHELIUM; ENZYME ACTIVITY; FEMALE; GENE; HOST CELL; IMMUNE RESPONSE; IMMUNIZATION; IMMUNOGENICITY; INCUBATION TIME; IRRADIATION; KNOCKOUT MOUSE; LYMPHOCYTE ACTIVATION; LYMPHOMA; MOUSE; NITRATION; NONHUMAN; PRIORITY JOURNAL; SPLEEN CELL; STATISTICAL SIGNIFICANCE; TUMOR CELL; TUMOR REJECTION;

ANIMALS; CELL DIVISION; CULTURE MEDIA, CONDITIONED; LYMPHOCYTES; LYMPHOMA; MICE; MICE, KNOCKOUT; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; NITRIC OXIDE SYNTHASE TYPE II; NITRIC OXIDE SYNTHASE TYPE III; NITRITES; THYMOMA; THYMUS NEOPLASMS; TUMOR CELLS, CULTURED;

EID: 1642576227     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-03-1807     Document Type: Article

References (61)

1. Moncada, S., Palmer, R. M. J., and Higgs, E. A. Nitric oxide: physiology, pathophysiology, and pharmacology. Pharmacol. Rev., 43: 109-142, 1991.
2. Knowles, R. G., and Moncada, S. Nitric oxide synthase in mammals Biochem. J., 298: 249-258, 1994.
3. Elfering, S. L., Sarkela, T. M., and Giulivi, C. Biochemistry of mitochondrial nitric-oxide synthase. J. Biol. Chem., 277: 38079-38086, 2002.
4. Zhao, H., Dugas, N., Mathiot, C., Delmer, A., Dugas, B., Sigaux, F., and Kolb, J-P. B-cell chronic lymphocytic leukemia cells express a functional inducible nitric oxide synthase displaying anti-apoptotic activity. Blood, 92: 1031-1043, 1998.
5. Mannick, J. B., Miao, X. Q., and Stamler, J. S. Nitric oxide inhibits Fas-induced apoptosis. J. Biol. Chem., 272: 24125-24128, 1997.
6. Arnold, R. E., and Weigent, D. A. The production of nitric oxide in EL4 lymphoma cells overexpressing growth hormone. J. Neuroimmunol., 134: 82-94, 2003.
7. Fukumura, D., and Jain, R. K. Role of nitric oxide in angiogenesis and microcirculation in tumors. Cancer Metastasis Rev., 17: 77-89, 1998.
8. Carmeliet, P., and Jain, R. K. Angiogenesis in cancer and other diseases. Nature (Lond.), 407: 249-257, 2000.
9. Xie, K., and Fidler, I. J. Therapy of cancer metastasis by activation of the inducible nitric oxide synthase. Cancer Metastasis Rev., 17: 55-75, 1998.
10. Kwak, J-Y., Han, M. K., Choi, K-S., Park, I-H., Park, S-Y., Sohn, M-H., Kim, U-H., McGregor, J. R., Samlowski, W. E., and Yim, C-Y. Cytokines secreted by lymphokine-activated killer cells induce endogenous nitric oxide synthesis and apoptosis in DLD-1 colon cancer cells. Cell. Immunol., 203: 84-94, 2000.
11. Lee, V. Y., McClintock, D. S., Santore, M. T., Budinger, G. R. S., and Chandel, N. S. Hypoxia sensitizes cells to nitric oxide-induced apoptosis. J. Biol. Chem., 277: 16067-16074, 2002.
12. Jenkins, D. C., Charles, I. G., Thomsen, L. L., Moss, D. W., Holmes, L. S., Baylis, S. A., Rhodes, P., Westmore, K., Emson, P. C., and Moncada, S. Roles of nitric oxide in tumor growth. Proc. Natl. Acad. Sci. USA, 92: 4392-4396, 1995.
13. Xie, K., Huang, S., Dong, Z., Juang, S-H., Gutman, M., Xie, Q-W., Nathan, C., and Fidler, I. J. Transfection with the inducible nitric oxide synthase gene suppresses tumorigenicity and abrogates metastasis by K-1735 murine melanoma cells. J. Exp. Med., 181: 1333-1343, 1995.
14. Ambs, S., Merriam, W. G., Ogunfusika, M. O., Bennett, W. P., Ishibe, N., Hussain, S. P., Tzeng, E. E., Geller, D. A., Billiar, T. R., and Harris, C. C. p53 and vascular endothelial growth factor regulate tumor growth of NOS2-expressing human carcinoma cells. Nat. Med., 4: 1371-1376, 1998.
15. Shi, Q., Huang, S., Jiang, W., Kutach, L. S., Ananthaswamy, H. N., and Xie, K. Direct correlation between nitric oxide synthase II inducibility and metastatic ability of UV-2237 murine fibrosarcoma cells carrying mutant p53. Cancer Res., 59: 2072-2075, 1999.
16. Thomsen, L., and Miles, D. W. Role of nitric oxide in tumour progression: lessons from human tumours. Cancer Metastasis Rev., 17: 107-118, 1998.
17. Leek, R. D., Lewis, C. E., Whitehouse, R., Greenall, M., Clarke, J., and Harris, A. L. Association of macrophage infiltration with angiogenesis and prognosis in invasive breast cancer. Cancer Res., 56: 4625-4629, 1996.
18. Leek, R. D., Lewis, C. E., and Harris, A. L. The role of macrophages in tumour angiogenesis. In: R. Bicknell, C. E. Lewis, and N. Ferrara (eds.), Tumour Angiogenesis, pp. 81-99. Oxford, England: Oxford University Press, 1997.
19. Stuehr, D. J., and Nathan, C. F. Nitric oxide. A macrophage product responsible for cytostasis and respiratory inhibition in tumor target cells. J. Exp. Med., 169: 1543-1555, 1989.
20. Keller, R., Geiges, M., and Keist, R. L-arginine-dependent reactive nitrogen intermediates as mediators of tumor cell killing by activated macrophages. Cancer Res., 50: 1421-1425, 1990.
21. Cui, S., Reichner, J. S., Mateo, R. B., and Albina, J. E. Activated murine macrophages induce apoptosis in tumor cells through nitric oxide-dependent or -independent mechanisms. Cancer Res., 54: 2462-2467, 1994.
22. Ambs, S., Merriam, W. G., Bennett, W. P., Felley-Bosco, E., Ogunfusika, M. O., Oser, S. M., Klein, S., Shields, P. G., Billiar, T. R., and Harris, C. C. Frequent nitric oxide synthase-2 expression in human colon adenomas: implication for tumor angiogenesis and colon cancer progression. Cancer Res., 58: 334-341, 1998.
23. Yim, C. Y., Bastian, N. R., Smith, J. C., Hibbs, J. B., and Samlowski, W. E. Macrophage nitric oxide synthesis delays progression of ultraviolet light-induced murine skin cancers. Cancer Res., 53: 5507-5511, 1993.
24. Dinapoli, M. R., Calderon, C. L., and Lopez, D. M. The altered tumoricidal capacity of macrophages isolated from tumor-bearing mice is related to reduced expression of the inducible nitric oxide synthase gene. J. Exp. Med., 183: 1323-1329, 1996.
25. + T cells in the antitumor immune response. J. Exp. Med., 188: 2357-2368, 1998.
26. Amber, I. J., Hibbs, J. B. J., Taintor, R. R., and Vavrin, Z. The L-arginine dependent effector mechanism is induced in murine adenocarcinoma cells by culture supernatant from cytotoxic activated macrophages. J. Leukocyte Biol., 43: 187-192, 1988.
27. Moore, M. W., Carbone, F. R., and Bevan, M. J. Introduction of soluble protein into the class I pathway of antigen processing and presentation. Cell, 54: 777-785, 1988.
28. Laubach, V. E., Shesely, E. G., Smithies, O., and Sherman, P. A. Mice lacking inducible nitric oxide synthase are not resistant to lipopolysaccharide-induced death. Proc. Natl. Acad. Sci. USA, 92: 10688-10692, 1995.
29. Huang, P. L., Huang, Z., Mashimo, H., Bloch, K. D., Moskowitz, M. A., Bevan, J. A., and Fishman, M. C. Hypertension in mice lacking the gene for endothelial nitric oxide synthase. Nature (Lond.), 377: 239-242, 1995.
30. Mosi, R., Seguin, B., Cameron, B., Amankwa, L., Darkes, M. C., and Fricker, S. P. Mechanistic studies on AMD6221: a ruthenium-based nitric oxide scavenger. Biochem. Biophys. Res. Commun., 292: 519-529, 2002.
31. Sandhu, J. K., Privora, H. F., Wenckebach, G., and Birnboim, H. C. Neutrophils, nitric oxide synthase, and mutations in the mutatect murine tumor model. Am. J. Pathol., 156: 509-518, 2000.
32. Dyall, R., Vasovic, L. V., Clynes, R. A., and Nikolic-Zugic, J. Cellular requirements for the monoclonal antibody-mediated eradication of an established solid tumour. Eur. J. Immunol., 29: 30-37, 1999.
33. Mayhew, T. M., and Sharma, A. K. Sampling schemes for estimating nerve-fiber size. II. Methods for nerve trunks of mixed fascicularity. J. Anat., 139: 45-58, 1984.
34. Kimura, M., Amemiya, K., Yamada, T., and Suzuki, J. Quantitative method for measuring adjuvant-induced granuloma angiogenesis in insulin-treated diabetic mice. J. Pharmacobio-Dyn., 9: 442-446, 1986.
35. Hu, D-E., Beauregard, D. A., Bearchell, M. C., Thomsen, L. L., and Brindle, K. M. Early detection of tumour immune-rejection using magnetic resonance imaging. Br. J. Cancer, 88: 1135-1142, 2003.
36. Misko, T. P., Schilling, R. J., Salvemini, D., Moore, W. M., and Currie, M. G. A fluorometric assay for measurement of nitrite in biological samples. Anal. Biochem., 214: 11-16, 1993.
37. Ju, D. W., Tao, Q., Lou, G., Bai, M., He, L., Yang, Y., and Cao, X. Interleukin 18 transfection enhances anti-tumor immunity induced by dendritic cell-tumor cell conjugates. Cancer Res., 61: 3735-3740, 2001.
38. Ke, Y., Ma, H., and Kapp, J. A. Antigen is required for the activation of effector activities, whereas interleukin 2 is required for the maintenance of memory in ovalbumin-specific, CD8+ cytotoxic T lymphocytes. J. Exp. Med., 187: 49-57, 1998.
39. Anthony, M. L., Zhao, M., and Brindle, K. M. Inhibition of phosphatidylcholine biosynthesis following induction of apoptosis in HL-60 cells. J. Biol. Chem., 274: 19686-19692, 1999.
40. Brossart, P., Goldrath, A. W., Butz, E. A., Martin, S., and Bevan, M. J. Virus-mediated delivery of antigenic epitopes into dendritic cells as a means to induce CTL. J. Immunol., 158: 3270-3276, 1997.
41. Vasovic, L. V., Dyall, R., Clynes, R. A., Ravetch, J. V., and Nikolic-Zugic, J. Synergy between an antibody and CD8(+) cells in eliminating an established tumor. Eur. J. Immunol., 27: 374-382, 1997.
42. Minev, B. R., McFarland, B. J., Spiess, P. J., Rosenberg, S. A., and Restifo, N. P. Insertion signal sequence fused to minimal peptides elicits specific Cd8+ T-cell responses and prolongs survival of thymoma-bearing mice. Cancer Res., 54: 4155-4161, 1994.
43. Zhou, F., Rouse, B. T., and Huang, L. Prolonged survival of thymoma-bearing mice after vaccination with a soluble-protein antigen entrapped in liposomes: a model study. Cancer Res., 52: 6287-6291, 1992.
44. Ramprasad, M. P., Fischer, W., Witztum, J. L., Sambrano, G. R., Quehenberger, O., and Steinberg, D. The 94-Kda to 97-Kda mouse macrophage membrane-protein that recognizes oxidized low-density-lipoprotein and phosphatidylserine-rich liposomes is identical to macrosialin, the mouse homolog of human Cd68. Proc. Natl. Acad. Sci. USA, 92: 9580-9584, 1995.
45. Gal, A., Tamir, S., Kennedy, L. J., Tannenbaum, S. R., and Wogan, G. N. Nitrotyrosine formation, apoptosis, and oxidative damage: relationships to nitric oxide production in SJL mice bearing the RcsX tumor. Cancer Res., 57: 1823-1828, 1997.
46. Ischiropoulos, H. Biological tyrosine nitration: a pathophysiological function of nitric oxide and reactive oxygen species. Arch. Biochem. Biophys., 356: 1-11, 1998.
47. Thomsen, L. L., Scott, J. M. J., Topley, P., Knowles, R. G., Keerie, A-J., and Frend, A. J. Selective inhibition of inducible nitric oxide synthase inhibits tumor growth in vivo: studies with 1400W, a novel inhibitor. Cancer Res., 57: 3300-3304, 1997.
48. Pieper, G. M., Roza, A. M., Adams, M. B., Hilton, G., Johnson, M., Felix, C. C., Kampalath, B., Darkes, M., Wanggui, Y., Cameron, B., and Fricker, S. P. A ruthenium (III) polyaminocarboxylate complex, a novel nitric oxide scavenger, enhances graft survival and decreases nitrosylated heme protein in models of acute and delayed cardiac transplant rejection, J. Cardiovasc. Pharmacol., 39: 441-448, 2002.
49. Nathan, C. Nitric oxide as a secretory product of mammalian cells. FASEB J., 6: 3051-3064, 1992.
50. Chin, K., Kurashima, Y., Ogura, T., Tajiri, H., Yoshida, S., and Esumi, H. Induction of vascular endothelial growth factor by nitric oxide in human glioblastoma and hepatocellular carcinoma cells. Oncogene, 15: 437-442, 1997.
51. Ziche, M., Morbidelli, L., Choudhuri, R., Zhang, H-T., Donnini, S., Granger, H. J., and Bicknell, R. Nitric oxide synthase lies downstream from vascular endothelial growth factor-induced but not basic fibroblast growth factor-induced angiogenesis. J. Clin. Investig., 99: 2625-2634, 1997.
52. Thomsen, L. L., Miles, D. W., Happerfield, L., Bobrow, L. G., Knowles, R. G., and Moncada, S. Nitric oxide synthase activity in human breast cancer. Br. J. Cancer, 72: 41-44, 1995.
53. Thomsen, L. L., Lawton, F. G., Knowles, R. G., Beesley, J. E., Riveros-Moreno, V., and Moncada, S. Nitric oxide synthase activity in human gynecological cancer. Cancer Res., 54: 1352-1354, 1994.
54. Dong, Z., Staroselsky, A. H., Qi, X., Xie, K., and Fidler, I. J. Inverse correlation between expression of inducible nitric oxide synthase activity and production of metastasis in K-1735 murine melanoma cells. Cancer Res., 54: 789-793, 1994.
55. Bogdan, C. Nitric oxide and the immune response. Nat. Immunol., 2: 907-916, 2001.
56. Rosenberg, S. A. Progress in human tumour immunology and immunotherapy. Nature (Lond.), 411: 380-384, 2001.
57. Shrikant, P., and Mescher, M. F. Control of syngeneic tumor growth by activation of CD8+ T cells: efficacy is limited by migration away from the site and induction of nonresponsiveness. J. Immunol., 162: 2858-2866, 1999.
58. Brown, G. C., and Borutaite, V. Nitric oxide inhibition of mitochondrial respiration and its role in cell death. Free Radic. Biol. Med., 26: 925-935, 2002.
59. Konopka, T. E., Barker, J. E., Bamford, T. L., Guida, E., Anderson, R. L., and Stewart, A. G. Nitric axide synthase II gene disruption: implications for tumor growth and vascular endothelial growth factor production. Cancer Res., 61: 3182-3187, 2001.
60. Shi, Q., Xiong, Q., Wang, B., Le, X., Khan, N. A., and Xie, K. Influence of nitric oxide synthase II gene disruption on tumor growth and metastasis. Cancer Res., 60: 2579-2583, 2000.
61. Wang, B., Xiong, Q., Shi, Q., Tan, D., Le, X., and Xie, K. Genetic disruption of host nitrix oxide synthase II gene impairs melanoma-induced angiogenesis and suppresses pleural effusion. Int. J. Cancer. 91: 607-611, 2001.